
|Videos|June 8, 2015
PD-1 Inhibitor Yields Responses in Hepatocellular Carcinoma
Author(s)Anthony B. El-Khoueiry, MD
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
Advertisement
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma. The data were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
Low-Dose CT Screening Reduces Lung Cancer–Specific Mortality
2
FDA Approves Companion Diagnostic for Pembrolizumab in Esophageal/GEJ Carcinoma
3
Durvalumab/SBRT May Limit Tumor Progression in Early-Stage NSCLC
4
Frontline IO-Combos, Next-Generation ADCs: Evolutions in Endometrial Cancer
5






















































